Because certain CSCs express transferrin receptor (TFRC) and prostate-specific membrane antigen (PSMA), TFRC and PSMA could be useful biomarkers for the directed imaging and targeted therapy of CSCs in cancer care. This evidence concerns the gene FOLH1 and cancer.